Simulect Injection, Powder, For Solution
Product Images NDC 0078-0331

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Simulect (NDC 0078-0331). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Simulect 01

This appears to be a graph showing the Kaplan-Meier estimate of the percentage of subjects who experience death, graft loss, or their first rejection episode within the first year (0-12 months) after undergoing dual therapy. The x-axis may represent different time points, with 6 months being the first data point shown. The y-axis appears to show the percentage of subjects experiencing the defined events. The graph shows that at 6 months, approximately 50% of subjects have experienced one of the defined events.*

FDA Label Image

Figure 1: Kaplan-meier Estimate Of The Percentage Of Subjects With Death, Graft Loss Or First Rejection Episode (dual Therapy) (Simulect 02)

This appears to be a packaging label for the drug "Simulect" by the pharmaceutical company Novartis. The label shows the dosage information for a 10mg single-dose vial of the drug for injection.*

FDA Label Image

Simulect 03

Simulect is a medication produced by Novartis and is available in single dose vials of 20mg for injection. No other information is available due to the poor quality of the text.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.